Journal article
Imatinib mesylate in children and adolescents with cancer
Abstract
Imatinib is an inhibitor of the BCR-ABL fusion gene product that characterizes chronic myeloid leukemia (CML), and of the related tyrosine kinases c-KIT and platelet-derived growth factor (PDGF) receptor. The drug is now included as front-line therapy for CML and Philadelphia chromosome-positive acute lymphoblastic leukemia in children and adolescents, though valid concerns about serious late sequelae remain unresolved and are important issues …
Authors
Barr RD
Journal
Pediatric Blood & Cancer, Vol. 55, No. 1, pp. 18–25
Publisher
Wiley
Publication Date
July 15, 2010
DOI
10.1002/pbc.22484
ISSN
1545-5009